Cargando…

History and progress of hypotheses and clinical trials for Alzheimer’s disease

Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pei-Pei, Xie, Yi, Meng, Xiao-Yan, Kang, Jian-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799833/
https://www.ncbi.nlm.nih.gov/pubmed/31637009
http://dx.doi.org/10.1038/s41392-019-0063-8
_version_ 1783460376200871936
author Liu, Pei-Pei
Xie, Yi
Meng, Xiao-Yan
Kang, Jian-Sheng
author_facet Liu, Pei-Pei
Xie, Yi
Meng, Xiao-Yan
Kang, Jian-Sheng
author_sort Liu, Pei-Pei
collection PubMed
description Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients. There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis. However, the ultimate etiology of AD remains obscure. In this review, we discuss the main hypotheses of AD and related clinical trials. Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD. The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD. We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD.
format Online
Article
Text
id pubmed-6799833
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-67998332019-10-21 History and progress of hypotheses and clinical trials for Alzheimer’s disease Liu, Pei-Pei Xie, Yi Meng, Xiao-Yan Kang, Jian-Sheng Signal Transduct Target Ther Review Article Alzheimer’s disease (AD) is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its main pathological features are cerebral atrophy, amyloid plaques, and neurofibrillary tangles in the brains of patients. There are various descriptive hypotheses regarding the causes of AD, including the cholinergic hypothesis, amyloid hypothesis, tau propagation hypothesis, mitochondrial cascade hypothesis, calcium homeostasis hypothesis, neurovascular hypothesis, inflammatory hypothesis, metal ion hypothesis, and lymphatic system hypothesis. However, the ultimate etiology of AD remains obscure. In this review, we discuss the main hypotheses of AD and related clinical trials. Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD. The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD. We further propose that fluoxetine, a selective serotonin reuptake inhibitor, has the potential to treat AD. Nature Publishing Group UK 2019-08-23 /pmc/articles/PMC6799833/ /pubmed/31637009 http://dx.doi.org/10.1038/s41392-019-0063-8 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Review Article
Liu, Pei-Pei
Xie, Yi
Meng, Xiao-Yan
Kang, Jian-Sheng
History and progress of hypotheses and clinical trials for Alzheimer’s disease
title History and progress of hypotheses and clinical trials for Alzheimer’s disease
title_full History and progress of hypotheses and clinical trials for Alzheimer’s disease
title_fullStr History and progress of hypotheses and clinical trials for Alzheimer’s disease
title_full_unstemmed History and progress of hypotheses and clinical trials for Alzheimer’s disease
title_short History and progress of hypotheses and clinical trials for Alzheimer’s disease
title_sort history and progress of hypotheses and clinical trials for alzheimer’s disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799833/
https://www.ncbi.nlm.nih.gov/pubmed/31637009
http://dx.doi.org/10.1038/s41392-019-0063-8
work_keys_str_mv AT liupeipei historyandprogressofhypothesesandclinicaltrialsforalzheimersdisease
AT xieyi historyandprogressofhypothesesandclinicaltrialsforalzheimersdisease
AT mengxiaoyan historyandprogressofhypothesesandclinicaltrialsforalzheimersdisease
AT kangjiansheng historyandprogressofhypothesesandclinicaltrialsforalzheimersdisease